Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

109.35
+4.624.41%
Post-market: 109.350.00000.00%19:30 EDT
Volume:483.38K
Turnover:52.51M
Market Cap:1.60B
PE:-12.32
High:110.41
Open:106.45
Low:105.04
Close:104.73
52wk High:155.29
52wk Low:26.20
Shares:14.67M
Float Shares:8.64M
Volume Ratio:1.88
T/O Rate:5.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-30.28
PE(LYR):-12.09

Loading ...

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MT Newswires Live
·
Apr 22

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

TIPRANKS
·
Apr 22

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

TIPRANKS
·
Apr 22

Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug, Reuters Reports

MT Newswires Live
·
Apr 22

Inhibrx Biosciences Shares Jump 6.2% Premarket After Reuters Report Co's Experimental Cancer Drug Draws Interest From Merck, Rivals

THOMSON REUTERS
·
Apr 22

Exclusive-Merck, Rivals Interested in Inhibrx Experimental Cancer Drug Tied to Keytruda, Sources Say

THOMSON REUTERS
·
Apr 22

EXCLUSIVE-Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Reuters
·
Apr 22

Exclusive-Inhibrx Considers Spinoff of Two Cancer Therapies, Sources Say

THOMSON REUTERS
·
Apr 22

Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study

Dow Jones
·
Apr 22

Inhibrx Provides Clinical Update on Ozekibart (Inbrx-109) in Late Line Colorectal Cancer

THOMSON REUTERS
·
Apr 22

Inhibrx to host webcast clinical update on ozekibart in late-line colorectal cancer

Reuters
·
Apr 21

Inhibrx to Host Webcast Presentation to Provide Clinical Update on Ozekibart (Inbrx-109) in Late Line Colorectal Cancer

THOMSON REUTERS
·
Apr 21

Stifel Initiates Inhibrx Biosciences at Buy With $150 Price Target

MT Newswires Live
·
Apr 08

Inhibrx Biosciences Initiated at Buy by Stifel

Dow Jones
·
Apr 08

Inhibrx initiated with a Buy at Stifel

TIPRANKS
·
Apr 08